Navigation Links
Evista Not A Cure For Heart Disease

Evista is the market name of the drug raloxifene HCl is manufactured by drug maker Eli Lilly & Co. a study was conducted which showed that Evista// , a drug used to treat osteoporosis in women, did not prevent heart attacks. The study analyzed 10,000 women in 26 countries for a period of seven years. It was studied whether if this drug given daily for the study period would lower the risks of heart attack and breast cancer in postmenopausal women who either had heart disease or were at high risk for heart attack.

Raloxifene HCl is mainly used to treat and prevent osteoporosis in postmenopausal women. But since this study proved that the drug did not prevent heart attacks the company wanted to reinforce for physicians that Evista should not be prescribed for cardioprotection. Lilly Chief Medical Officer Alan Breier said in a statement that they have gathered new data on Evista's potential to reduce the risk of invasive breast cancer in postmenopausal women. It plans to submit the details of its study to the Food and Drug Administration for review. But further analysis would be needed and precautionary measures to be taken before announcing the use of the drug with respect to breast cancer.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... , ... February 08, 2016 , ... ... co-occur frequently. While a significant number of women and men with eating disorders ... trauma itself, that best predicts the development of an eating disorder. , ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort ... is time to make a change in public health,” states Carole Baggerly, Director ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... (NADL), only four states in the U.S. require dental technicians to be certified ... in the dental industry, NADL created the “What’s In Your Mouth?” campaign to ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information to ... combines three elements to cut the cost of providing employee healthcare benefits by ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... 8, 2016  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... communication from the U.S. Food and Drug Administration (FDA) ... a partial clinical hold on the clinical studies being ... for pacritinib. This clinical hold impacts part of the ... will also affect planned clinical trials. ...
(Date:2/5/2016)... Amgen (NASDAQ: AMGN ) will present at ... at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, in ... Meline , executive vice president and chief financial officer at ... presentation can be accessed from the Events Calendar on Amgen,s ... webcast will also be available on Amgen,s website for at ...
Breaking Medicine Technology: